Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide Pharmacokinetics with Itraconazole and Rifampin
NCT06363630Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of golcadomide in non-Hodgkin lymphoma (NHL), B cell lymphoma, follicular lymphoma (FL) and 1 more (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration and 1 more. Started Apr 2024; status: completed.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)B cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06363630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363630.